Medscape4d
Osimertinib OS Benefit Persists Among Patients With EGFR+ NSCLC
Osimertinib (Tagrisso, AstraZeneca), continues to provide an overall survival (OS) benefit after definitive chemoradiotherapy (CRT) in patients with unresectable stage III epidermal growth factor ...
Nasdaq8d
J&J : RYBREVANT + LAZCLUZE Outperforms Osimertinib In Phase 3 Trial For EGFR-Mutated Lung Cancer
Head-to-head comparison data versus osimertinib showed RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) significantly extended OS in the first-line treatment of patients with locally ...
Medscape7d
‘Take a Photograph’: Trial Shows Big Survival Gain in Advanced EGFR-Mutant NSCLC
PARIS — Final overall survival results from the phase 3 MARIPOSA study showed that the first-line amivantamab plus lazertinib combination extended overall survival notably more than osimertinib ...
Yahoo Finance9d
New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings
together reinforce osimertinib as an effective, safe and convenient treatment for patients with EGFR-mutated lung cancer across stages and lines of treatment." Susan Galbraith, Executive Vice ...
Nasdaq15d
J&J Says Rybrevant, Lazcluze Combo Significantly Improved Survival In Lung Cancer Patients
(RTTNews) - Johnson & Johnson (JNJ) Thursday reported positive data from the Phase 3 MARIPOSA study evaluating rybrevant plus lazcluze versus osimertinib in the first-line treatment of patients ...